Acute Migraine Acute Treatment Guidelines

1. Initial Assessment & Mild Migraine

• For patients with mild migraine, start with an NSAID (e.g., ibuprofen 400‑600 mg, naproxen 500‑550 mg, or aspirin 900‑1000 mg), acetaminophen 1000 mg, or the combination aspirin 250 mg + acetaminophen 250 mg + caffeine 65 mg. [Citation @1, @3]
• Verify that the patient has used an adequate dose before escalating to stronger therapy. [Citation @2, @3]

2. First‑Line Therapy for Moderate‑to‑Severe Migraine

• Initiate combination therapy with a triptan plus an NSAID (or acetaminophen when NSAIDs are contraindicated) as the first‑line regimen; add an antiemetic if nausea or vomiting is present. [Citation @1, @2] – high‑certainty recommendation
• Preferred high‑certainty combination: sumatriptan 50‑100 mg + naproxen 500‑550 mg. [Citation @2, @4]
• Alternative high‑certainty combination: rizatriptan 10 mg + naproxen 500‑550 mg. [Citation @2, @4]

3. Efficacy of Triptan + NSAID Combination (Evidence from Large Trials)

[Citation @4] – high‑certainty

4. Alternatives When NSAIDs Are Contraindicated

• Use triptan + acetaminophen 1000 mg (e.g., sumatriptan + acetaminophen). [Citation @1, @3]
• Rizatriptan 10 mg + acetaminophen yields 300 additional patients per 1,000 achieving pain freedom at 2 h compared with acetaminophen alone, and 250 additional patients per 1,000 achieving sustained pain freedom at 48 h. [Citation @4] – high‑certainty

5. Choice of Triptan & Formulation for Severe Nausea/Vomiting

• Any of the following triptans may be used based on response, cost, or route: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan. [Citation @1, @3]
• Non‑oral formulations for patients with significant nausea/vomiting:
  
  • Sumatriptan 6 mg subcutaneous (fastest onset, highest efficacy)
  • Zolmitriptan 5 mg nasal spray
  • Rizatriptan 10 mg orally disintegrating tablet
    [Citation @1, @3]
• Add an antiemetic (metoclopramide 10 mg IV/IM or prochlorperazine 10 mg IV/IM) when needed. [Citation @1, @3]

6. Step‑Up Options After First‑Line Failure

• Second‑line (after adequate trial of triptan + NSAID/acetaminophen):
  
  • CGRP antagonists (gepants) – rimegepant 75 mg, ubrogepant 50‑100 mg, or zavegepant 10 mg nasal spray. [Citation @1, @3]
  • Dihydroergotamine – 1 mg IM/SC or 0.5‑1 mg nasal spray. [Citation @1, @3]
• Third‑line (if second‑line agents fail or are not tolerated):
  
  • Lasmiditan 50‑100 mg – reserved for patients who have failed all other acute treatments because of adverse‑effect concerns (e.g., driving restrictions). [Citation @1, @3]

7. Timing of Treatment

• Treat migraine as early as possible after onset; early treatment markedly improves efficacy compared with delayed dosing. [Citation @3] – high‑certainty
• Initiating combination therapy at onset is superior to sequential monotherapy. [Citation @3] – high‑certainty

8. Medication‑Overuse Prevention

• Limit triptan use to <10 days per month and NSAID use to <15 days per month to avoid medication‑overuse headache. [Citation @1, @3]
• If acute treatment is needed ≥4 days per week, start a preventive therapy regimen rather than increasing acute medication frequency. [Citation @1, @3]

9. Absolute Contraindications to Triptans

• Uncontrolled hypertension (>140/90 mmHg) [Citation @2]
• Coronary artery disease or history of myocardial infarction [Citation @3]
• Cerebrovascular disease (prior stroke or TIA) [Citation @2]

10. Medications to Avoid

• Opioids (e.g., hydromorphone, morphine, oxycodone) and butalbital‑containing compounds should never be used for acute migraine because they increase medication‑overuse headache risk and provide inferior outcomes. [Citation @1, @3] – high‑certainty

11. Cost Considerations

[Citation @4] – high‑certainty

• Prescribe the least costly effective option that meets the patient’s clinical needs. [Citation @1, @3]

12. Special Populations

• Pregnancy & Lactation – Discuss risks/benefits of all agents; acetaminophen is generally considered the safest option. [Citation @3]
• Most triptans and NSAIDs carry pregnancy category C or D ratings. [Citation @3]

13. Common Pitfalls & Best Practices

• Underdosing – Ensure adequate doses (e.g., sumatriptan 100 mg, naproxen 500‑550 mg). [Citation @2, @3]
• Delayed treatment – Waiting until pain is severe reduces efficacy. [Citation @3]
• Monotherapy when combination indicated – Combination therapy is superior for moderate‑to‑severe migraine. [Citation @1, @2, @4]
• Premature class switching – Trial at least 2‑3 different triptans at adequate doses before declaring class failure. [Citation @1, @3]
• Use of opioids – Leads to worse long‑term outcomes and higher medication‑overuse headache risk. [Citation @1, @3]

Acute Migraine Management: Evidence‑Based Combination Therapy

Recommended Initial Cocktail

• For adults with moderate‑to‑severe acute migraine and no cardiovascular contraindications, the first‑line regimen is a triptan combined with an NSAID; add an antiemetic when nausea or vomiting is present【@1】.

Efficacy of Triptan + NSAID Combination (high‑certainty evidence)

• Combining a triptan with an NSAID yields 130 additional patients per 1,000 achieving sustained pain relief at 48 h compared with either agent alone【@2】【@3】.
• The same combination provides 110 more patients per 1,000 achieving pain freedom at 2 h【@2】.
• It reduces the need for rescue medication by 160 fewer patients per 1,000【@2】【@3】.

Specific Drug Combinations

Sumatriptan + Naproxen (most studied)

• The sumatriptan‑naproxen pair has the strongest evidence base (high‑certainty) for acute migraine relief【@2】【@3】.

Alternative Triptan + NSAID Pairings

• Rizatriptan + naproxen also demonstrates benefit, though with slightly less evidence than the sumatriptan‑naproxen combo【@3】【@2】.
• Any triptan (e.g., almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan) can be paired with any NSAID (e.g., aspirin, celecoxib, diclofenac, ibuprofen, naproxen) and still provide superior efficacy over monotherapy【@1】【@4】.

Alternatives When NSAIDs Are Contraindicated

• A triptan combined with acetaminophen is recommended for patients who cannot take NSAIDs【@1】【@4】.
• Rizatriptan + acetaminophen produces 300 additional patients per 1,000 achieving pain freedom at 2 h versus acetaminophen alone【@5】【@3】【@2】.
• The same regimen yields 250 more patients per 1,000 with sustained pain freedom at 48 h【@5】.

Antiemetic Use (high‑certainty evidence)

• Add an antiemetic to the triptan‑NSAID regimen when severe nausea or vomiting is present【@6】【@7】.
• For severe nausea/vomiting, consider a non‑oral triptan formulation (subcutaneous, nasal spray, or orally disintegrating tablet) together with an antiemetic【@6】【@8】.

Assessment and Treatment Algorithm

Initial Assessment

• Confirm that migraine intensity is moderate‑to‑severe【@1】.
• Verify absence of cardiovascular contraindications to triptans【@1】.
• Evaluate the severity of nausea/vomiting【@6】.

Medication Selection

• Without severe nausea: oral triptan (sumatriptan, rizatriptan, or eletriptan preferred for rapid onset) plus an oral NSAID (naproxen 500‑550 mg or ibuprofen 400‑600 mg)【@1】【@4】.
• With severe nausea/vomiting: non‑oral triptan (e.g., sumatriptan 6 mg subcutaneous, zolmitriptan nasal spray, or rizatriptan ODT) plus an antiemetic (e.g., metoclopramide 10 mg) and an NSAID if tolerated【@6】.

Timing of Administration

• Administer the combination as early as possible after migraine onset to maximize efficacy; early treatment improves outcomes compared with delayed dosing【@6】【@4】.

Medication‑Overuse Prevention (high‑certainty evidence)

• Limit triptan use to fewer than 10 days per month to avoid medication‑overuse headache【@6】【@4】.
• Limit NSAID use to fewer than 15 days per month【@6】【@4】.
• If attacks are frequent and require more frequent acute treatment, initiate preventive therapy【@6】【@7】.

Cost Considerations (high‑certainty evidence)

• Generic triptan‑NSAID combinations have an annual cost of approximately $500, markedly lower than newer agents such as gepants ($5,994) or lasmiditan ($6,668)【@2】【@5】.

Contraindications and Safety (high‑certainty evidence)

• When triptans are contraindicated (e.g., cardiovascular disease), use NSAID monotherapy or a combination analgesic (acetaminophen + aspirin + caffeine)【@1】【@8】.
• Do not use triptans in patients with uncontrolled hypertension, coronary artery disease, prior stroke or TIA【@2】, or peripheral vascular disease【@1】【@5】.

Medications to Avoid (high‑certainty evidence)

• Opioids and butalbital‑containing compounds should not be used for acute migraine because they increase the risk of medication‑overuse headache and provide inferior outcomes【@1】【@6】【@8】.

Route of Administration Preferences (high‑certainty evidence)

• Oral formulations are preferred by most patients when nausea is not severe【@1】【@7】.
• Subcutaneous sumatriptan 6 mg offers the fastest onset and highest efficacy, with a lower number‑needed‑to‑treat for pain freedom compared with oral formulations【@5】.

All statements are supported by high‑certainty evidence where indicated.